Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine

Davis, Tyler; Farag, Sherif

doi:10.2147/ijn.s47037

Cited by 17 publications

(5 citation statements)

References 82 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This liposomal formulation increased the biodistribution and half-life of vincristine sulfate and allowed for a higher dose of intensification compared to bare vincristine. In the clinical trial phase 2, patients in the second or greater relapse treated weakly with 2.25 mg/m 2 of VSLI achieved complete remission of 20% and an overall response rate of 35% [146,147].…”

Section: Nanosystems In the Treatment Of Lymphoid Malignanciesmentioning

confidence: 99%

Nanocarriers as Magic Bullets in the Treatment of Leukemia

et al. 2020

View full text Add to dashboard Cite

Leukemia is a type of hematopoietic stem/progenitor cell malignancy characterized by the accumulation of immature cells in the blood and bone marrow. Treatment strategies mainly rely on the administration of chemotherapeutic agents, which, unfortunately, are known for their high toxicity and side effects. The concept of targeted therapy as magic bullet was introduced by Paul Erlich about 100 years ago, to inspire new therapies able to tackle the disadvantages of chemotherapeutic agents. Currently, nanoparticles are considered viable options in the treatment of different types of cancer, including leukemia. The main advantages associated with the use of these nanocarriers summarized as follows: i) they may be designed to target leukemic cells selectively; ii) they invariably enhance bioavailability and blood circulation half-life; iii) their mode of action is expected to reduce side effects. FDA approval of many nanocarriers for treatment of relapsed or refractory leukemia and the desired results extend their application in clinics. In the present review, different types of nanocarriers, their capability in targeting leukemic cells, and the latest preclinical and clinical data are discussed.

show abstract

Section: Nanosystems In the Treatment Of Lymphoid Malignanciesmentioning

confidence: 99%

Nanocarriers as Magic Bullets in the Treatment of Leukemia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The agent is delivered in 1 hour weekly infusions. In adult Ph-negative ALL patients, vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation 53. Trials are ongoing, testing liposomal vincristine sulfate in pediatric patients.…”

Section: Non-targeted Therapies And/or Agentsmentioning

confidence: 99%

“…In adult Ph-negative ALL patients, vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation. 53 Trials are ongoing, testing liposomal vincristine sulfate in pediatric patients. For example, the pivotal trial, “Vincristine Sulfate Liposome Injection Marqibo ® In Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapsed ALL” is currently recruiting patients in the UK and is sponsored by the Therapeutic Advances in Childhood Leukemia Consortium (NCT 02879643).…”

Section: Non-targeted Therapies And/or Agentsmentioning

confidence: 99%

Novel agents for the treatment of childhood leukemia: an update

Eryilmaz¹,

Canpolat²

2017

OTT

View full text Add to dashboard Cite

Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.

show abstract

“…In addition, it affects the immune cells of the body( Fujimura et al, 2018 ), can activate adaptive immunity by inducing DNA damage, promoting cytotoxic T lymphocytes (CTLs) infiltration into tumor sites, and enhancing the antitumor immune response( Harding et al, 2017 ; Serpico et al, 2020 ). VCR is used clinically for the treatment of acute lymphatic leukemia, breast cancer, malignant lymphoma, small cell lung cancer and pediatric solid tumors( Davis and Farag, 2013 ), and can also be used in combination with chemotherapy( Hagemeister et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Research on the loading and release kinetics of the vincristine sulfate liposomes and its anti-breast cancer activity

Liu,

et al. 2024

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine

Cited by 17 publications

References 82 publications

Nanocarriers as Magic Bullets in the Treatment of Leukemia

Nanocarriers as Magic Bullets in the Treatment of Leukemia

Novel agents for the treatment of childhood leukemia: an update

Research on the loading and release kinetics of the vincristine sulfate liposomes and its anti-breast cancer activity

Contact Info

Product

Resources

About